Claim Missing Document
Check
Articles

Found 2 Documents
Search

ANALISIS INTERAKSI OBAT PADA PASIEN COVID-19 DENGAN PENYAKIT ASMA DI INSTALASI RAWAT INAP RSD GUNUNG JATI trisna lestari; Lilis Kholida Nuiah; Aan Junaedi
Jurnal Farmasindo: Jurnal Penelitian dan Pengabdian Masyarakat Vol. 9 No. 1 (2025): Juni
Publisher : Politeknik Indonusa Surakarta, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.46808/farmasindo.v9i1.252

Abstract

Covid-19 with treatment of asthma must be considered. Because comorbid patients experience polypharmacy, this study aims to determine patient profiles, drug interactions based on mechanism,severity and significance of the use of Covid-19 drugs with asthma comorbidities at the inpatient installation of RSD Gunung Jati Cirebon.This study is a non eksperimental study with retrospective data collection, namely medical record data of patients with confirmed Covid-19 with comorbid asthma. Sampling using total sampling technique as many as 51 medical records. The study was conducted from November 2022 ti July 2023. Determination of drug interactions using the drugs.com application. Descriptive statistical data analysis in the form of percentages and tables. Based on the result of a study of Covid-19 patients with comorbid asthma, the age group was dominated by the group of 46-55 years (31%) and the gender of 32 patients (62%) was female. There were 14 potential drug interaction events from 51 patienst with a pharmacodynamic mechanism of action in 31 cases (91,18%) and pharmacokinetics in 3 cases (8,82%). Based on the level of severity, namely 7 cases (20,59%) for major interactions, 21 cases (61,76%) for moderate, 6 cases (17,65%) for minor. Covid-19 drug interactions with asthma comorbidities are mostly pharmacodynamic mechanism and moderate in severity.
ANALISIS KESESUAIAN BIAYA RIIL TERHADAP TARIF INA- CBG`s PADA PENGOBATAN PASIEN RAWAT INAP DIARE DI RUMAH SAKIT SUMBER HURIP CIREBON Trisna Lestari; Denmas Teo Bimantara; Nur Rahmi Hidayati; Aan Kunaedi; Giska Amelia
Jurnal Farmasindo: Jurnal Penelitian dan Pengabdian Masyarakat Vol. 10 No. 1 (2026): Juni
Publisher : Politeknik Indonusa Surakarta, Indonesia

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.46808/farmasindo.v10i1.337

Abstract

The management of hospitalized patients with diarrhea incurs significant costs, particularly for JKN participants under the INA-CBG’s package payment system. Discrepancies between actual hospital costs and INA-CBG’s rates can result in financial losses for healthcare facilities. This study analyzes the alignment of actual treatment costs with INA-CBG’s rates for inpatients with diarrhea at Sumber Hurip Hospital in Cirebon, and evaluates patient characteristics and treatment profiles. The study employs a quantitative, observational approach with a retrospective design. A total of 213 medical records of inpatients with diarrhea from January to December 2024 were collected using random sampling. Data analysis was performed using SPSS with descriptive and bivariate correlation tests. The majority of patients were aged 18–59 years (100%), female (63.8%), admitted to Class III (64.7%), had a length of stay of 3–5 days (86.39%), and had mild cases (91.55%). Treatment was dominated by Diagit (52.95%) and New Diatab (43.01%). The average INA-CBG rate was Rp434,257,800, while the average actual cost reached Rp568,133,904, resulting in a shortfall of Rp133,876,104. Factors with a significant influence (p<0.05) were age, length of hospital stay, secondary diagnosis, severity level, and care class, while gender had no effect.